REFERENCES (In Order)

Hota, S. S. (2007). Contamination, disinfection, and cross-colonization: Are hospital surfaces reservoirs for nosocomial infection? Clinical Infectious Diseases, 39(8), 1182-1189.

Kelly, C. P., & LaMont, J. T. (2008). Clostridium difficile—more difficult than ever. New England Journal of Medicine, 359(18), 1932-1940.

Leffler, D. A., & Lamont, J. T. (2015). Clostridium difficile infection. New England Journal of Medicine, 372(16), 1539-1548.

Apic.org. (2019). Clostridioides difficile Infection and Pseudomembranous Colitis. [online] Available at: https://text.apic.org/toc/healthcare-associated-pathogens-and-diseases/clostridioides-difficile-infection-and-pseudomembranous-colitis.

Cleveland Clinic. (n.d.). Pseudomembranous Colitis: Symptoms, Causes, Treatment & Prevention. [online] Available at: https://my.clevelandclinic.org/health/diseases/17718-pseudomembranous-colitis.

Goudarzi, M., Seyedjavadi, S.S., Goudarzi, H., Mehdizadeh Aghdam, E. and Nazeri, S. (2014). Clostridium difficileInfection: Epidemiology, Pathogenesis, Risk Factors, and Therapeutic Options. Scientifica, 2014, pp.1–9. doi:https://doi.org/10.1155/2014/916826.

Schäffler, H. and Breitrück, A. (2018). Clostridium difficile – From Colonization to Infection. Frontiers in Microbiology, 9(646). doi:https://doi.org/10.3389/fmicb.2018.00646.

PMC, E. (2021). Europe PMC. [online] europepmc.org. Available at: https://europepmc.org/article/NBK/nbk1377.

Surawicz, C.M. and McFarland, L.V. (1999). Pseudomembranous colitis: causes and cures. Digestion, [online] 60(2), pp.91–100. doi:https://doi.org/10.1159/000007633.

Mayo Clinic (2019). Pseudomembranous colitis - Symptoms and causes. [online] Mayo Clinic. Available at: https://www.mayoclinic.org/diseases-conditions/pseudomembranous-colitis/symptoms-causes/syc-20351434.

Ellis, R.R. (n.d.). What Is Pseudomembranous Colitis? [online] WebMD. Available at: https://www.webmd.com/ibd-crohns-disease/ulcerative-colitis/pseudomembranous-colitis.

Cruz-López, A.;, Morfin-Otero, F.;, Maldonado-Garza, R.;, Garza-González, H.J.;, An, E., Martínez-Meléndez, A., Cruz-López, F., Morfin-Otero, R., Maldonado-Garza, H.J., Garza-González, E., 2022. An Update on Clostridioides difficile Binary Toxin. Toxins 2022, Vol. 14, Page 305 14, 305.

Czepiel, J., Krutova, M., Mizrahi, A., Khanafer, N., Enoch, D.A., Patyi, M., Deptuła, A., Agodi, A., Nuvials, X., Pituch, H., Wójcik-Bugajska, M., Filipczak-Bryniarska, I., Brzozowski, B., Krzanowski, M., Konturek, K., Fedewicz, M., Michalak, M., Monpierre, L., Vanhems, P., Gouliouris, T., Jurczyszyn, A., Goldman-Mazur, S., Wultańska, D., Kuijper, E.J., Skupień, J., Biesiada, G., Garlicki, A., 2021. Mortality Following Clostridioides difficile Infection in Europe: A Retrospective Multicenter Case-Control Study. Antibiotics 10, 299.

De Roo, A.C., Regenbogen, S.E., De Roo, A.C., Regenbogen, S.E., 2020a. Clostridium difficile Infection: An Epidemiology Update. Clin Colon Rectal Surg 33, 49–57.

Fingertips | Department of Health and Social Care [WWW Document], 2024 URL https://fingertips.phe.org.uk/search/difficile#page/4/gid/1/pat/159/par/K02000001/ati/15/are/E92000001/iid/91902/age/205/sex/4/cat/-1/ctp/-1/yrr/1/cid/4/tbm/1

Lim, S.C., Knight, D.R., Riley, T. V., 2020. Clostridium difficile and One Health. Clinical Microbiology and Infection 26, 857–863.

Slimings, C., Riley, T. V., 2021. Antibiotics and healthcare facility-associated Clostridioides difficile infection: systematic review and meta-analysis 2020 update. Journal of Antimicrobial Chemotherapy 76, 1676–1688.

Turner, N.A., Anderson, D.J., 2020. Hospital Infection Control: Clostridioides difficile. Clin Colon Rectal Surg 33, 98. https://doi.org/10.1055/S-0040-1701234

UKHSA Clostridioides difficile: guidance, data and analysis - GOV.UK [WWW Document], 2024. URL https://www.gov.uk/government/collections/clostridium-difficile-guidance-data-and-analysis

Kelly, C.P., & LaMont, J.T. (2008). Clostridium difficile—more difficult than ever. New England Journal of Medicine, 359(18), 1932–1940. DOI:10.1056/nejmra0707500

 Louie, T.J., et al. (2011). Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine, 364(5), 422–431. DOI:10.1056/nejmoa1010636

Wilcox, M.H., et al. (2017). Bezlotoxumab for prevention of recurrent Clostridium difficile infection. New England Journal of Medicine, 376(4), 305–317. DOI:10.1056/nejmoa1602615

Cammarota, G., et al. (2017). Fecal microbiota transplantation for the treatment of Clostridium difficile infection. Clinical Microbiology and Infection, 23(5), 291–298. DOI:10.1016/j.cmi.2016.12.001

Smits, W.K., et al. (2016). Clostridium difficile infection. Nature Reviews Disease Primers, 2, 16020. Link

Ouwehand, A.C., et al. (2002). Probiotic and other functional microbes: from markets to mechanisms. Proceedings of the Nutrition Society, 61(1), 1–13. DOI:10.1079/PNS2002156

Kuehne, S.A., et al. (2014). The role of toxins in Clostridium difficile infection. Infection and Immunity, 82(9), 3793–3800. DOI:10.1128/IAI.01604-14

Bikard, D., et al. (2014). Exploiting CRISPR-Cas systems for genome editing in bacteria. Nature Protocols, 9(3), 517–529. DOI:10.1038/nprot.2014.038

Understanding Clostridium Difficile Infection (C. Diff), n.d., YouTube video, viewed 3 December 2024, https://www.youtube.com/watch?v=Bpe94DaI6Pc .

Hota, S. S. (2007). Contamination, disinfection, and cross-colonization: Are hospital surfaces reservoirs for nosocomial infection? Clinical Infectious Diseases, 39(8), 1182-1189.

Kelly, C. P., & LaMont, J. T. (2008). Clostridium difficile—more difficult than ever. New England Journal of Medicine, 359(18), 1932-1940.

Leffler, D. A., & Lamont, J. T. (2015). Clostridium difficile infection. New England Journal of Medicine, 372(16), 1539-1548.